Reading Time: < 1 minuteIntroduction Testosterone deficiency, or hypogonadism, affects approximately 2-4 million American men, manifesting as fatigue, depression, reduced libido, and diminished emotional resilience. Vogelxo (testosterone 1% gel), a U.S. FDA-approved topical androgen replacement therapy (TRT), delivers bioidentical testosterone transdermally, achieving physiological serum levels. While TRT is well-established for ameliorating somatic symptoms, its psychological sequelae—particularly on emotional intelligence (EI) and interpersonal relationships—remain underexplored. EI, encompassing self-awareness, self-regulation, motivation, empathy, and social skills per Mayer and Salovey's model, is pivotal for relational satisfaction. This 24-month prospective cohort study investigates Vogelxo's influence on EI and dyadic functioning in hypogonadal American males aged 40-65, hypothesizing enhancements … Continue reading →